These combination treatment strategies can improve clinical outcomes in HR+/HER2+ or ERBB2-mutant breast cancer, potentially overcoming resistance to ET arising from crosstalk between the ER and HER2 signaling pathways. The gene discussed is ERBB2; the disease is breast carcinoma.